SENAI

The Women’s Entrepreneurship Accelerator Celebrates Three-Year Anniversary Milestone at Geneva Event with the Launch of the Digital Innovation Challenge for Women Start-ups in Partnership with International Telecommunication Union

Retrieved on: 
Friday, March 17, 2023
Women, Other Philanthropy, Technology, Thought Leadership, DEI (Diversity, Equity and Inclusion), Start-Up, Consumer, Environmental, Social and Governance (ESG), Fashion, Cosmetics, Retail, Teens, Small Business, Professional Services, Other Technology, Philanthropy, Fund Raising, Internet, Entrepreneur, Other Consumer, Online Retail, ECA, Entrepreneurship, Communication, Partnership, Violence, Face, Reconstruction, International Telecommunication Union, Policy, Curriculum, WED, Woman, Multimedia, Mentorship, SENAI, Sustainable Development Goals, PwC, ILO, WEA, ITU, International Trade Centre, Development, United Nations Global Compact, Risk, Commerce, UN, Mary Kay, International Bank for Reconstruction and Development, Knowledge, International Labour Organization, Digital, ITC, International Training Centre of the International Labour Organization, Sustainable Development Goal 5, Environment, EXPO, European Central Bank, Toy, Mobile phone, Construction

Hosted by the International Telecommunication Union (ITU) in Geneva, and convening WEA’s five other UN partners, the WEA anniversary event highlighted the need to invest in women entrepreneurs through digital to scale their businesses.

Key Points: 
  • Hosted by the International Telecommunication Union (ITU) in Geneva, and convening WEA’s five other UN partners, the WEA anniversary event highlighted the need to invest in women entrepreneurs through digital to scale their businesses.
  • The event also served to highlight the risks posed by the digital transformation underway in perpetuating existing patterns of gender inequality.
  • Key take-aways from the event included:
    Existing innovation and start-up eco-systems greatly lack gender diversity and are characterized by an uneven distribution of opportunity and financial resources.
  • The assessment included a series of 19 actionable recommendations to address the institutional gaps that exist for women entrepreneurs.

CMPC, one of Latin America's largest pulp and paper companies, partners with CNI and SOSA to optimize its supply chain efficiency

Retrieved on: 
Monday, August 1, 2022
Carbon, Chilean, Association of Car Rental Industry Systems Standards, Environment, Municipal solid waste, Forestry, Social work, LG, Industry, CEO, Culture, Government, Partnership, Euvaldo Lodi Institute of Rio de Janeiro, Solution, National Service Learning Conference, CNI, POC, Adoption, Organization, SESI, SENAI, Technology, CMPC, Schneider Electric, Cellulose, Soil, Efficiency, NEW, Innovation, IEL, HP, Industrial, VPG, Tissue paper, Renewable energy, Cryptocurrency, Agriculture

NEW YORK, Aug. 1, 2022  /PRNewswire/ -- CMPC, one of Latin America's largest pulp and paper companies, has announced a partnership with CNI and SOSA, the global open innovation company, to improve the efficiency and sustainability of CMPC's forestry supply chain in Brazil.

Key Points: 
  • Through the partnership, CMPC and SOSA will work to identify advanced tech solutions during a four-month innovation project.
  • NEW YORK, Aug. 1, 2022 /PRNewswire/ --CMPC, one of Latin America's largest pulp and paper companies, has announced a partnership with CNI and SOSA, the global open innovation company, to improve the efficiency and sustainability of CMPC's forestry supply chain in Brazil.
  • CMPC Brazil aims to harness SOSA's open innovation capabilities to implement cutting-edge tech solutions that will optimize shipments and operational efficiency and ultimately contribute to reducing its carbon footprint even more.
  • Throughout the scouting and validation process, SOSA will consider the best-fit startup candidates to match CMPC's tech requirements, infrastructure, and local regulations.

Gerdau Graphene Develops Ultra-Strong Graphene-Enhanced Plastics

Retrieved on: 
Tuesday, June 7, 2022
Polymer, Human, Paganini Competition, Chemistry, Goal, PP, Instituto Millenium, Transport, CEO, Partnership, PVC, PS, Advanced Materials, Thermal conductivity, Graphene, Rubber industry in Malaysia, GLOBE, Face, Plastic, Nanocomposite, PE, Nanotechnology, Nobel Prize, UV, Industry, SAO, Polyethylene, Invention, Petroleum, SENAI, Thermoplastic, Carbon fibers

Graphene can be mixed with plastics, lending its incredible strength to the plastic matrix and making the combined plastic material much stronger.

Key Points: 
  • Graphene can be mixed with plastics, lending its incredible strength to the plastic matrix and making the combined plastic material much stronger.
  • Gerdau Graphene is developing graphene additives for virgin resins as well as post-industrial and post-consumer recycled plastics and polymers, including PP, PE, polystyrene (PS), polycarbonate (PC), PVC, and more.
  • We are now addressing all of these goals," said Alexandre Corra, CEO of Gerdau Graphene.
  • Launched in 2021 by Gerdau, the largest producer of long steel in the Americas, through its Gerdau Next program, Gerdau Graphene enables businesses to harness the revolutionary properties of graphene to deliver industry-leading products.

HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 Variants Protect Against Infection of Upper Airways, Important for Preventing Transmission

Retrieved on: 
Tuesday, April 5, 2022
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Hospital, National, ELife, Therapy, Vaccination, Death, SENAI, Infection, Vaccine, Research, Pathology, National Institute, RNA, Immunity, Omicron, National Institute of Allergy and Infectious Diseases, Immune system, Safety, HDT, RNA transfection, Throat, COVID-19, Extrapyramidal system, Animal, Disease

In addition, the animal studies showed that even when not matched against variants, HDT Bios RNA vaccine protects against lower respiratory tract infection and disease regardless of viral strain.

Key Points: 
  • In addition, the animal studies showed that even when not matched against variants, HDT Bios RNA vaccine protects against lower respiratory tract infection and disease regardless of viral strain.
  • The advantage of using a lower dose of RNA not only is improved overall safety, but also enables HDT Bio to deliver multiple RNA molecules in one vaccine targeting multiple variants of the virus.
  • The results showed that HDT Bio vaccines matched to a variant shut down the virus in the upper respiratory tract, which includes nasal passages, throat and windpipe.
  • HDT Bio is conducting clinical trials of its COVID-19 RNA vaccine in the U.S. and internationally with partners in Brazil, South Korea and China.

Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine

Retrieved on: 
Monday, January 17, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, All-China Federation of Industry and Commerce, Vaccination, Research, Technology, Ministry, Safety, Vaccine, Clinical trial, Incidence, Biotechnology, RNA, COVID-19, Population, Adult, Volunteering, Phase II, Health, Infection, Industry, Education, HDT, Doctor of Philosophy, Therapy, Immune system, Engineering, Principal, SENAI, Partnership, Trial of the century, Science

SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT.

Key Points: 
  • SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT.
  • The first was in India with our partner Gennova Biopharmaceuticals which has moved the vaccine into Phase 2 and Phase 3 trials.
  • HDT Bio has other partnerships for its RNA COVID-19 vaccine, including in South Korea and China.
  • HDT Bios innovative vaccine, which also will undergo a Phase 1 trial in the U.S. , uses its proprietary lipid nanoparticle carrier system for delivery of RNA.

HDT Bio Partner Quratis Doses First Healthy Volunteers in Phase 1 Trial of HDT Bio’s RNA COVID-19 Vaccine in South Korea

Retrieved on: 
Monday, December 13, 2021
Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, RNA, RNA transfection, Vaccination, Tuberculosis, SENAI, Infection, COVID-19, Cancer, COVID-19 vaccine, Vaccine, Research, Safety, Therapy, HDT, Immune system, DNA, GMP, Technology

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, and Korean biotech Quratis Inc. announced today the first healthy volunteers in South Korea have been dosed in a Phase 1 trial of HDT Bios revolutionary COVID-19 RNA vaccine for distribution in South Korea and neighboring countries.

Key Points: 
  • HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, and Korean biotech Quratis Inc. announced today the first healthy volunteers in South Korea have been dosed in a Phase 1 trial of HDT Bios revolutionary COVID-19 RNA vaccine for distribution in South Korea and neighboring countries.
  • Successful development of HDT Bios vaccine will enable Quratis to manufacture our next-generation COVID-19 RNA vaccine and make it available across much of East Asia.
  • Quratis is developing HDT Bios RNA vaccine under the name QTP104.
  • Currently, Quratis is operating a fully equipped GMP plant, which produces DNA plasmid, RNA, enzyme, protein, and other bio products.

HDT Bio Partners with Brazil’s SENAI CIMATEC to Advance RNA COVID-19 Vaccine to Fight Pandemic

Retrieved on: 
Tuesday, August 31, 2021
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Industry, Population, Technology, SENAI, Infection, All-China Federation of Industry and Commerce, Therapy, Engineering, Immune system, Innovation, Science, Research, Technology transfer, RNA, Global health, Doctor of Philosophy, HDT, Biotechnology, Ministry, Safety, Vaccine, Brazilians, Education, Sale, Vaccination, API, COVID-19, Pharmaceutical industry

SENAI CIMATEC will conduct those clinical trials under the name Vaccine RNA MCTI-CIMATEC-HDT.

Key Points: 
  • SENAI CIMATEC will conduct those clinical trials under the name Vaccine RNA MCTI-CIMATEC-HDT.
  • This agreement with SENAI CIMATEC will help build Brazils own vaccine and drug manufacturing capabilities, and provide the countrys population with greater access to advanced medicines, said HDT Bio CEO Steve Reed.
  • HDT Bios innovative vaccine uses its proprietary LIONTM, lipid-based carrier system for delivery of RNA.
  • Under the agreement, HDT Bio has granted SENAI CIMATEC a non-exclusive license to its technology for research, manufacture and sale of HDT-301 in Brazil.